Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Nearly three decades since the remarkable cloning of Dolly the sheep, it has all gone quiet on the human cloning front.

A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Scientists grew a microscopic fungus into a more efficient — and meat-like — edible protein by tweaking just two genes with ...

HIV treatment has entered a revolutionary new era, one where a single yearly injection can keep the virus undetectable, and ...

Genetic engineering is moving from the lab bench into clinics, farms, and even family planning decisions, promising to change ...